HBP Stock Overview
Helix BioPharma Corp. operates as an immune-oncology company in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Helix BioPharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.19 |
| 52 Week High | CA$0.26 |
| 52 Week Low | CA$0.15 |
| Beta | -0.74 |
| 1 Month Change | -9.52% |
| 3 Month Change | -11.63% |
| 1 Year Change | -13.64% |
| 3 Year Change | -78.41% |
| 5 Year Change | -63.46% |
| Change since IPO | -78.89% |
Recent News & Updates
Shareholder Returns
| HBP | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -5.0% | -5.8% | -0.6% |
| 1Y | -13.6% | -37.3% | 3.9% |
Return vs Industry: HBP exceeded the Canadian Biotechs industry which returned -37.3% over the past year.
Return vs Market: HBP underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| HBP volatility | |
|---|---|
| HBP Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: HBP has not had significant price volatility in the past 3 months.
Volatility Over Time: HBP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9 | Jacek Antas | www.helixbiopharma.com |
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Helix BioPharma Corp. Fundamentals Summary
| HBP fundamental statistics | |
|---|---|
| Market cap | CA$43.59m |
| Earnings (TTM) | -CA$5.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.3x
P/E RatioIs HBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBP income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$5.94m |
| Earnings | -CA$5.94m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HBP perform over the long term?
See historical performance and comparison